Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $26.63 million. The enterprise value is $4.60 million.
| Market Cap | 26.63M |
| Enterprise Value | 4.60M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, before market open.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 5.32 million shares outstanding. The number of shares has increased by 0.26% in one year.
| Shares Outstanding | 5.32M |
| Shares Change (YoY) | +0.26% |
| Shares Change (QoQ) | +0.46% |
| Owned by Insiders (%) | 2.91% |
| Owned by Institutions (%) | 8.84% |
| Float | 5.16M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.31 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.69, with zero debt.
| Current Ratio | 8.69 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -63.30% and return on invested capital (ROIC) is -88.03%.
| Return on Equity (ROE) | -63.30% |
| Return on Assets (ROA) | -58.30% |
| Return on Capital (ROIC) | -88.03% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$961,892 |
| Employee Count | 17 |
| Asset Turnover | -0.10 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $755 in taxes.
| Income Tax | 755 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.28% in the last 52 weeks. The beta is 1.09, so Lipocine's price volatility has been similar to the market average.
| Beta (1Y) | 1.09 |
| 52-Week Price Change | +21.28% |
| 50-Day Moving Average | 4.67 |
| 200-Day Moving Average | 3.72 |
| Relative Strength Index (RSI) | 52.62 |
| Average Volume (30 Days) | 67,122 |
Short Selling Information
The latest short interest is 278,427, so 5.24% of the outstanding shares have been sold short.
| Short Interest | 278,427 |
| Short Previous Month | 108,889 |
| Short % of Shares Out | 5.24% |
| Short % of Float | 5.40% |
| Short Ratio (days to cover) | 1.91 |
Income Statement
In the last 12 months, Lipocine had revenue of -$2.85 million and -$16.35 million in losses. Loss per share was -$3.14.
| Revenue | -2.85M |
| Gross Profit | -2.85M |
| Operating Income | -17.93M |
| Pretax Income | -16.35M |
| Net Income | -16.35M |
| EBITDA | -16.32M |
| EBIT | -16.35M |
| Loss Per Share | -$3.14 |
Balance Sheet
The company has $22.04 million in cash and no debt, giving a net cash position of $22.04 million or $4.15 per share.
| Cash & Cash Equivalents | 22.04M |
| Total Debt | n/a |
| Net Cash | 22.04M |
| Net Cash Per Share | $4.15 |
| Equity / Book Value | 20.37M |
| Book Value Per Share | 3.83 |
| Working Capital | 20.23M |
Cash Flow
In the last 12 months, operating cash flow was -$11.87 million and capital expenditures -$13,167, giving a free cash flow of -$11.88 million.
| Operating Cash Flow | -11.87M |
| Capital Expenditures | -13,167 |
| Free Cash Flow | -11.88M |
| FCF Per Share | -$2.25 |
Margins
Gross margin is 100.00%, with operating and profit margins of 628.98% and 573.60%.
| Gross Margin | 100.00% |
| Operating Margin | 628.98% |
| Pretax Margin | 573.57% |
| Profit Margin | 573.60% |
| EBITDA Margin | 572.56% |
| EBIT Margin | 573.57% |
| FCF Margin | 416.69% |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.26% |
| Shareholder Yield | -0.26% |
| Earnings Yield | -61.40% |
| FCF Yield | -44.60% |
Analyst Forecast
The average price target for Lipocine is $33.00, which is 558.68% higher than the current price. The consensus rating is "Buy".
| Price Target | $33.00 |
| Price Target Difference | 558.68% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 1:17.
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:17 |
Scores
Lipocine has an Altman Z-Score of -7.5 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.5 |
| Piotroski F-Score | 1 |